Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 12/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
| ▸ | SKP1 | P63208 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31536320 | 0.88 | SUV39H2 (0.49) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL30936771 | 0.84 | CTSK (0.51) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL30124591 | 0.84 | SUV39H2 (0.47) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL22499869 | 0.84 | SUV39H2 (0.47) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL29690023 | 0.84 | SUV39H2 (0.47) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL29182738 | 0.84 | SUV39H2 (0.47) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL29182735 | 0.84 | SUV39H2 (0.47) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL950966 | 0.81 | SUV39H2 (0.55) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL29265664 | 0.81 | SUV39H2 (0.55) | SUV39H2CTSKCKS1BSKP1SKP2 | |
| SCHEMBL950967 | 0.81 | SUV39H2 (0.55) | SUV39H2CTSKCKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168077-A1 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-01 | — | — | US | claimed |
| EP-2144877-A1 | NOVEL PYRIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS THEREOF | UCB Pharma, S.A. (BE) | 2010-01-20 | — | — | EP | claimed |
| WO-2008122378-A1 | NOVEL PYRIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS THEREOF | UCB PHARMA, S.A. (BE) | 2008-10-16 | — | — | WO | claimed |
| US-20100168077-A1 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168077-A1 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof | CYP4B1, CYP3A4, CYP2C19 | SUV39H2 3242/4885CTSK 2954/4885CKS1B 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.